Marie-Madeleine Dolmans

No ORCID on file · 54 papers in corpus · active 2002-2025

Study types

  • article 30
  • review 13
  • other 6
  • editorial 2
  • letter 2

Condition tags

  • endometriosis 25
  • mesh:D004715 23
  • adenomyosis 18
  • infertility 9
  • endometrioma 3
  • dyspareunia 1
  • chronic_pelvic_pain 1
  • mesh:D017699 1
  • dysmenorrhea 1
other 2025
Effectiveness of an anti-inflammatory diet before in vitro fertilisation in women with endometriosis: protocol for a randomised controlled trial
BMJ open ·doi:10.1136/bmjopen-2025-108596

INTRODUCTION: Endometriosis is a common, benign, chronic inflammatory disease with multiple consequences, from chronic pain to systemic comorbidities and poor quality of life. As it usually affects people of reproductive age, one of the mos…

article 2025
Endométriose et adénomyose: exploration des mécanismes inflammatoires et de leurs conséquences

/

other 2025
Generation of epithelial-stromal assembloids as an advanced in vitro model of impaired adenomyosis-related endometrial receptivity
Fertility and sterility ·doi:10.1016/j.fertnstert.2024.08.339

OBJECTIVE: To create a novel, more advanced in vitro model of human endometrium, using so-called assembloids, looking to explore endometrial receptivity in adenomyosis. DESIGN: Evaluation of assembloid responsiveness to hormonal stimulatio…

other 2025
Gonadotropin-releasing hormone antagonist in uterine adenomyosis: some light at the end of the tunnel
Fertility and sterility ·doi:10.1016/j.fertnstert.2025.06.013
article 2025
"Lifestyle and Medical Treatments in Endometriosis"
rct 2025
Linzagolix with and without hormonal add-back therapy for symptomatic uterine fibroids: PRIMROSE 1 & 2 long-term extension and withdrawal study
Fertility and sterility ·doi:10.1016/j.fertnstert.2025.06.016

OBJECTIVE: To evaluate whether oral linzagolix administered once daily for up to 52 weeks (extension study) at a dose of 100 mg or 200 mg with or without hormonal add-back therapy (ABT) (1.0 mg estradiol; 0.5 mg norethisterone acetate) can …

article 2025
"Modeling adenomyosis with organoids"
article 2025
"Oral GnRH antagonist for endometriosis"
article 2025
Temporal dynamics of uterine immune microenvironment remodeling in a murine model of adenomyosis
Molecular human reproduction ·doi:10.1093/molehr/gaaf057

Adenomyosis-the ectopic presence of endometrial glands and stroma within the myometrium-affects reproductive-age women and is associated with pain, bleeding, and subfertility, yet the immune events that precede pregnancy remain poorly defin…

article 2025
Traitements non-chirurgicaux de l'endométriose
article 2024
Abnormal uterine bleeding: The well-known and the hidden face
Journal of endometriosis and uterine disorders ·doi:10.1016/j.jeud.2024.100071

Abnormal uterine bleeding (AUB) is a bleeding from the uterine corpus that is abnormal in regularity, volume, frequency or duration. It encompasses heavy menstrual bleeding, irregular menstrual bleeding and intermenstrual bleeding, which ar…

letter 2024
Characterization of microRNA exosome content from endometrioma wall in vitro culture
Fertility and sterility ·doi:10.1016/j.fertnstert.2024.03.010
article 2024
Impaired endometrial receptivity in uterine adenomyosis

/

article 2023
Are lower levels of apoptosis and autophagy behind adenomyotic lesion survival?
Reproductive biomedicine online ·doi:10.1016/j.rbmo.2023.06.003
review 2023
Could IVF replace reproductive surgery? No, reproductive surgery is still very much alive
Reproductive biomedicine online ·doi:10.1016/j.rbmo.2023.01.015

Could IVF replace reproductive surgery? The answer is no. Reproductive surgery still has a place, at least in some indications that will be explored in this contribution. While IVF can offer infertile couples the chance to have a healthy ba…

article 2023
Endometriosis and adenomyosis: Similarities and differences
Best practice & research. Clinical obstetrics & gynaecology ·doi:10.1016/j.bpobgyn.2023.102432
article 2023
Endometriosis and Infertility

/

letter 2023
Evolution of uterine adenomyosis volume during and after GnRH antagonist (linzagolix) treatment: lessons for further clinical trials
Fertility and sterility ·doi:10.1016/j.fertnstert.2023.07.012
article 2023
Linzagolix for endometriosis-associated pain: key secondary efficacy endpoints from edelweiss 3, A phase 3, randomized, double-bind, placebo-controlled trial

/

article 2023
M2 macrophages enhance endometrial cell invasiveness by promoting collective cell migration in uterine adenomyosis
Reproductive biomedicine online ·doi:10.1016/j.rbmo.2023.01.001
editorial 2023
Uterine adenomyosis: Is there an impact on in vitro fertilization outcomes?
Fertility and sterility ·doi:10.1016/j.fertnstert.2023.12.027
article 2022
Fertility Preservation in Endometriosis

/

article 2022
SEUD Congress

8th Congress of the Society of Endometriosis and Uterine Disorders We have the pleasure and honor of inviting you to the 8th SEUD Annual congress (Society of Endometriosis and Uterine Disorders) which will be held in Athens, Greece from May…

review 2022
Uterine disorders and iron deficiency anemia
Fertility and sterility ·doi:10.1016/j.fertnstert.2022.08.011

Abnormal uterine bleeding (AUB) is a clinical entity which can lead to iron deficiency anemia. Classification according to the acronym PALM-COEIN (polyp, adenomyosis, leiomyoma, malignancy, and hyperplasia; coagulopathy, ovulatory dysfuncti…

review 2021
Can Endometriosis-Related Oxidative Stress Pave the Way for New Treatment Targets?
International journal of molecular sciences ·doi:10.3390/ijms22137138

Endometriosis is a disease of reproductive age characterized by chronic pelvic pain and infertility. Its pathogenesis is complex and still partially unexplained. However, there is increasing evidence of the role of chronic inflammation, imm…